Financial reports
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K/A
Departure of Directors or Certain Officers
21 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
18 Mar 24
8-K
Form of Parent Stockholder Support Agreement
6 Mar 24
8-K
Entry into a Material Definitive Agreement
7 Dec 23
8-K
Other Events
7 Dec 23
8-K
Revolutionizing the treatment of Cystic Fibrosis through our unique BOLT Phage therapy platform Investor Presentation / November 2023
29 Nov 23
8-K
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
8-K
Departure of Directors or Certain Officers
31 Oct 23
8-K
Departure of Directors or Certain Officers
18 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
29 Aug 23
Registration and prospectus
S-3/A
Shelf registration (amended)
28 Dec 23
SC TO-I/A
Issuer tender offer statement (amended)
12 Dec 23
S-3
Shelf registration
7 Dec 23
SC TO-I/A
Issuer tender offer statement (amended)
28 Nov 23
SC TO-I
Issuer tender offer statement
9 Nov 23
25-NSE
Exchange delisting
12 Jun 23
424B3
Prospectus supplement
9 Jun 23
S-3
Shelf registration
2 Jun 23
S-8
Registration of securities for employees
29 Mar 23
D
$7.48 mm in equity / options, sold $1.46 mm, 10 investors
3 Mar 23
Proxies
DEF 14A
Definitive proxy
28 Jul 23
PRE 14A
Preliminary proxy
14 Jul 23
DEFA14A
Additional proxy soliciting materials
15 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
22 Mar 23
PRE 14A
Preliminary proxy
9 Mar 23
DEFA14A
Additional proxy soliciting materials
7 Jul 22
DEF 14A
Definitive proxy
7 Jul 22
PRE 14A
Preliminary proxy
21 Jun 22
Other
EFFECT
Notice of effectiveness
3 Jan 24
CORRESP
Correspondence with SEC
29 Dec 23
CORRESP
Correspondence with SEC
28 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
EFFECT
Notice of effectiveness
9 Jun 23
CORRESP
Correspondence with SEC
6 Jun 23
UPLOAD
Letter from SEC
6 Jun 23
EFFECT
Notice of effectiveness
14 Dec 21
CORRESP
Correspondence with SEC
9 Dec 21
UPLOAD
Letter from SEC
8 Dec 21
Ownership
SC 13G/A
Cystic Fibrosis Foundation
26 Mar 24
3
Initial statement of insider ownership
26 Mar 24
SC 13G
AMR Action Fund, L.P.
25 Mar 24
SC 13D
Flynn James E
22 Mar 24
3
JONATHAN S LEFF
21 Mar 24
3
Gregory Louis Merril
21 Mar 24
3
JESSE GOODMAN
21 Mar 24
4
James E Flynn
19 Mar 24
3
James E Flynn
19 Mar 24
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
19 Mar 24